- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Ipsen outlays $1bn for China-based Simcere's preclinical ADC | ||
| Di | Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma | ||
| Di | Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity | ||
| Di | Samsung Biologics to acquire Human Genome Sciences | ||
| Mo | BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push | ||
| Mo | UK approves Gilead's twice-yearly HIV PrEP drug | ||
| Mo | Trump administration ties pricing deals with another nine pharma companies | ||
| Mo | Cytokinetics receives FDA approval for MYQORZO tablets for oHCM | ||
| Mo | AstraZeneca pulls Andexxa from US market after post-marketing fatalities | ||
| Mo | MEDIPOST, Teikoku Seiyaku partner for CARTISTEM commercialisation in Japan | ||
| Mo | Novartis, US government reach agreement to lower drug prices | ||
| Fr | Nxera seeks schizophrenia programme buyer after Boehringer snub | ||
| Fr | Takeda to seek approval of plaque psoriasis pill on Phase III trial data | ||
| Fr | Eli Lilly's oral GLP-1RA maintains weight loss from injectable drugs | ||
| Fr | MHRA launches call for evidence on AI regulation in UK healthcare sector | ||
| Fr | J&J receives FDA approval for lung cancer therapy | ||
| Do | FDA approves meningioma label warning on Pfizer's contraceptive injection | ||
| Do | BIOSECURE Act set for Trump's signature after Congress approval | ||
| Do | EC approves Incyte's Minjuvi combo for follicular lymphoma | ||
| Do | Alnylam plans $250m investment in Norton manufacturing facility, US | ||
| 17.12. | CDC ends universal newborn hepatitis B vaccine recommendations | ||
| 17.12. | GSK obtains FDA approval for Exdensur in severe asthma | ||
| 17.12. | Harbour BioMed and BMS sign multi-specific antibody collab | ||
| 17.12. | Precision medicine approaches needed in oncology to match evolving SoC | ||
| 17.12. | INCOG reveals $200m injectable drug expansion in Indiana |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .